Glox Therapeutics Receives Share of £3M CF AMR Syndicate Fund to Combat Lung Infections

  • Glox Therapeutics has been awarded up to £500,000 from the £3 million Collaborative Discovery Programme (CDP) to develop precision antibiotics for cystic fibrosis (CF) lung infections.
  • The funding will support the company’s work on novel therapeutics to address antimicrobial-resistant lung infections in CF patients.

Glox Therapeutics, a company specialising in precision antibiotic therapies, has secured up to £500,000 in funding from the Collaborative Discovery Programme (CDP). The CDP, launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate with backing from the medical research charity LifeArc, is aimed at accelerating the development of new treatments for antimicrobial-resistant (AMR) infections in people with cystic fibrosis (CF).

Over 162,000 people globally live with CF, a genetic condition that causes thick mucus to accumulate in the lungs, making them vulnerable to bacterial infections. The rise of AMR, particularly to common pathogens such as Pseudomonas aeruginosa, is making these infections harder to treat with existing antibiotics. Glox Therapeutics is focused on developing potent new antibiotics through its proprietary bacteriocin engineering platform. These antibiotics are designed to target and eliminate drug-resistant bacteria without harming the human microbiome, providing an effective solution to CF-related lung infections.

The CDP is a collaborative initiative led by the CF AMR Syndicate, which includes organisations like the Medicines Discovery Catapult, LifeArc, and the Cystic Fibrosis Trust. It combines industry, academic, and clinical expertise to drive forward antimicrobial drug discovery and development for CF patients. As part of this partnership, Glox Therapeutics will have access to expert guidance and resources, which are expected to accelerate the development of its novel antibiotics.

Dr James Clark, CEO and Co-founder of Glox Therapeutics, commented on the importance of this funding: “We are grateful to LifeArc for the CDP funding, recognising the potential of Glox Therapeutics’ unique platform to address this urgent unmet need. The collaborative support, disease insights, and expert guidance of the CF AMR Syndicate will be incredibly valuable as we advance the development of our precision antibiotics to help improve the lives of patients.”

The collaborative approach is seen as essential in the fight against AMR in CF, with Dr Catherine Kettleborough, Head of Chronic Respiratory Infection Translational Challenge at LifeArc, noting the importance of collaboration in overcoming these challenges.

Sign up to the free weekly newsletter for all the latest biotech news, resources and podcasts.  Register here

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

UPCOMING EVENT

New from PharmaSource, CDMO Live (Rotterdam, May 7-8, 2025) brings together biopharma’s manufacturing leaders to optimise their outsourcing strategy.

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.